Literature DB >> 30320758

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes.

Michael Peled1, Marianne Strazza2, Adam Mor3.   

Abstract

Receptor-associated enzymes are the major mediators of cellular activation. These enzymes are regulated, at least in part, by physical interactions with cytoplasmic tails of the receptors. The interactions often occur through specific protein domains and result in activation of the enzymes. There are several methods to study interactions between proteins. While co-immunoprecipitation is commonly used to study domains that are required for protein-protein interactions, there are no assays that document the contribution of specific domains to activity of the recruited enzymes at the same time. Accordingly, the method described here combines co-immunoprecipitation and an on-bead enzymatic activity assay for simultaneous evaluation of interactions between proteins and associated enzymatic activation. The goal of this protocol is to identify the domains that are critical for physical interactions between a protein and enzyme and the domains that are obligatory for complete activation of the enzyme. The importance of this assay is demonstrated, as certain receptor protein domains contribute to the binding of the enzyme to the cytoplasmic tail of the receptor, while other domains are necessary to regulate the function of the same enzyme.

Mesh:

Substances:

Year:  2018        PMID: 30320758      PMCID: PMC6235382          DOI: 10.3791/58433

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  16 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

Authors:  Kelly-Ann Sheppard; Lori J Fitz; Julie M Lee; Christina Benander; Judith A George; Joe Wooters; Yongchang Qiu; Jason M Jussif; Laura L Carter; Clive R Wood; Divya Chaudhary
Journal:  FEBS Lett       Date:  2004-09-10       Impact factor: 4.124

3.  Serine/threonine protein phosphatase assays.

Authors:  Thomas McAvoy; Angus C Nairn
Journal:  Curr Protoc Mol Biol       Date:  2010-10

Review 4.  Selected signalling proteins recruited to the T-cell receptor-CD3 complex.

Authors:  Jatuporn Ngoenkam; Wolfgang W Schamel; Sutatip Pongcharoen
Journal:  Immunology       Date:  2017-09-05       Impact factor: 7.397

5.  The coreceptor programmed death 1 inhibits T-cell adhesion by regulating Rap1.

Authors:  Inbar Azoulay-Alfaguter; Marianne Strazza; Ariel Pedoeem; Adam Mor
Journal:  J Allergy Clin Immunol       Date:  2014-09-18       Impact factor: 10.793

6.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

7.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

8.  Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains.

Authors:  S Pluskey; T J Wandless; C T Walsh; S E Shoelson
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

9.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

Review 10.  Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.

Authors:  Wagner Ricardo Montor; Andrei Ronaldo Oliveira Silva Escartin Salas; Fabiana Henriques Machado de Melo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.